NEET PG 2024 exam tomorrow in 2 shifts: NBE adopts AIIMS process for results preparation

New Delhi- Through a notice, the National Board of Examinations in Medical Sciences (NBEMS) has informed about the preparation of the the National Eligibility and Entrance Test-Postgraduate (NEET PG) 2024 result.

As per the notice, NBEMS has informed that the authority has adopted the process which is currently being used by All India Institute of Medical Sciences (AIIMS) New Delhi for various examinations conducted in more than one shift, including but not limited to Institutes of National Importance Combined Entrance Test (INI-CET), in preparation of result for NEET-PG 2024. The date for the NEET PG 2024 result declaration has yet to be announced.

NEET PG 2024 is going to be held tomorrow i.e. 11th August 2024 in two shifts i.e. from 9 am to 12:30 pm and 3:30 pm. Earlier this exam was scheduled to be held on 23rd June 2024. 

For the NEET PG exam 2024, additional security measures are being taken by NBEMS and MoHFW (Govt. of India), therefore NEET PG will now be conducted in 185 test cities across the country. The exam is being held to admit medical graduates into 52,000 postgraduate seats available in India.

SCHEME OF NEET-PG 2024

The NEET PG exam comprises 200 Multiple Choice Questions with each question having 4 options in English only. Candidates are required to select the correct answer out of the 4 response options provided in each question. the examination time to complete the paper is 3 hours and 30 minutes. There shall be a 25% negative marking for incorrect answers. No marks will be deducted for unanswered questions.

The National Board of Examinations (NBE) was established in 1975 in New Delhi. It is an autonomous entity within the Ministry of Health and Family Welfare, Government of India. NBE conducts a few examinations such as DNB final (exit) examinations, Fellowship Entrance and Exit examinations, NEET-SS for admission to DM/Mch/DrNB superspecialty medical courses across India, etc.

To view the notice, click the link below

Powered by WPeMatico

No BMC registration, Doctor booked for running private hospital

Mumbai: A doctor cum owner of a private hospital in Kandivali, Maharashtra has been recently booked for allegedly running the hospital for a year without a valid license from the Brihanmumbai Municipal Corporation (BMC). 

During a surprise inspection at the hospital, BMC inspector Ganesh Kadam responsible for evaluating various establishments including hotels, hospitals, and crematoriums within R/South Ward inspected the hospital and found that it was functioning without a licence violating BMC regulations. 

Also read- Navi Mumbai doctor couple accused of duping medical shop owner of Rs 1.27 Crore

As per a TOI news report, the inspection took place on June 13 when Kadam visited the hospital that has been running for a year and asked the doctor to show the license of the hospital to prove that the hospital was registered under the corporation. In response, the doctor informed him that he had not registered the hospital with the BMC. 

After the inspection was completed, Kadam submitted a copy of his inspection report to Sahayak Hospital and gave the doctor time to register the hospital. However, the hospital was still not registered even after two months of the inspection. 

On August 6, Kadam registered a case under the Bombay Nursing Homes Registration Act, 1949 against the doctor. He has been booked and no arrest has been made yet. An investigation is underway. 

Bombay Nursing Homes Registration Act, 1949 provide for the registration and inspection of nursing Homes in the Province of Bombay and certain purposes Connected therewith. According to the Act, every hospital and nursing home in the city must be registered with the BMC. 

Medical Dialogues team had earlier reported that in its continuous battle to eradicate quackery in Telangana, several quacks pretending to be MBBS doctors were found administering medicines to people at illegal clinics putting their lives at risk. 

Also read- Udupi laparoscopic surgeon booked for alleged controversial tweet against Muslim community

Powered by WPeMatico

BFUHS Invites Applications For NEET 2024 Counselling, Releases Round 1 Schedule, register now

Punjab- Baba Farid University of Health Sciences (BFUHS) is inviting online applications for combined online counselling from eligible candidates on the basis of National Eligibility and Entrance Test-Undergraduate (NEET UG) 2024 for admission to UG Medical and Dental Courses in Government and Private Colleges and Minority Institutions in the state of Punjab.

The registration for combined online counselling for NEET UG 2024 has started and will end on August 15, 2024. Meanwhile, the 1st round of online counselling will begin on August 10 and will continue till September 05, 2024. The detailed schedule of the registration process and counselling of NEET UG 2024 is mentioned below-

REGISTRATION PROCESS SCHEDULE

S.NO

PARTICULARS

DATES

1

Availability of Prospectus on University website.

09 August 2024

2

The last date for applying online Admission Application Form through University Website.

15 August 2024

3

Last date for depositing fee of Rs. 5000 + 18% GST(Rs. 5900/-) & Rs. 2500 + 18% GST (Rs. 2950/-) for SC candidates through Online payment gateway.

16 August 2024.

4

Sports Category Candidates will submit printed/hard copies of the online submitted form personally (by hand) in the University along with a Sports Gradation Certificate issued by the Director, Sports, Punjab and other supporting self-attested copies of certificates/documents.

16 August 2024

5

Verification for eligibility of Christian Minority Quota Candidates for admission to MBBS/BDS Courses, session 2024 will be conducted at the Christian Minority-At Christian Medical College, Ludhiana.

09 to 17 August 2024

6

Verification for eligibility of Sikh Minority Quota Candidates for admission to MBBS/BDS Courses, session 2024 will be conducted at the Sikh Minority- At SGRD Institute of Medical Sciences & Research, Amritsar.

16 to 18 August 2024

FOR NRI CANDIDATES

S.NO

PARTICULARS

DATES

1

The last date for submitting the physical application form for the NRI quota (Application form for Eligibility certificate and admission application form for NRI candidates is separately available on the University website.

19 August 2024

2

Display of Provisional Merit List of candidates.

Upto 20 August 2024

3

Last date for submission of objections in Provisional Merit List(if any) by the NEET UG aspirants.

21 August 2024 (upto 05:00 PM).

4

In case there is any change in the Provisional Merit List after considering objections, the same will be displayed on the university website.

Upto 23 August 2024

1ST ROUND OF COUNSELLING SCHEDULE

S.NO

PARTICULARS

DATES

1

Choice filling for 1st Round of Online Counselling.

10.08.2024 to 24.08.2024.

2

Processing of Seat Allotment.

25.08.2024 to 27.08.2024

3

Display of Result

28.08.2024

4

Last date for submission of objections in Provisional Allotment List(if any) by the NEET UG aspirants. Note: Objections can be submitted only by personal appearance/visit along with relevant documents/records in the Admission Branch, BFUHS, Faridkot. Objections received through email will not be accepted.

29.08.2024 (upto 04:00 PM)

5

In case there is any change in provisional allotment after considering objections, the same will be displayed on the University website.

30.08.2024

6

Physical Reporting by candidates to the respective provisionally allotted colleges and deposition of six months tuition fee through University Payment Gateway available on the University website in Student Login.

31.08.2024 to 05.09.2024

To view the schedule, click the link below

Powered by WPeMatico

Odisha: SUM Ultimate Medicare saves 9-year-old with Acute Liver Failure using Plasma Exchange

Bhubaneswar: A city-based SUM Ultimate Medicare in Odisha successfully treated a 9-year-old girl with severe liver failure using plasma exchange, also known as liver dialysis, when liver transplantation was not an option.

The girl was brought to the hospital recently complaining of jaundice caused by a viral infection and got admitted under the care of the care of Dr Ayaskanta Singh, senior consultant and head of the department of gastroenterology in the hospital, news agency UNI reported.

The patient was subsequently shifted to the NICU under Dr Pradip Kumar Dey, Head of the Department of Paediatrics and Neonatology, as her condition deteriorated.

Also Read:Home Minister Amit Shah urges private sector to stress on research in medical sciences

As the patient was experiencing respiratory distress, it was decided by the team of doctors to go for plasma exchange, also known as liver dialysis, as the liver transplantation option was not available.

According to the UNI report, “This process is not generally attempted in the case of children,” Dr Gadadhar Panda, Associate Consultant in the Department of Gastroenterology, who was leading the procedure, said on Tuesday.

“The death rate in such cases is close to 90 per cent,” Dr. Dey said.

Dr Sambit Bhuyan, Associate Consultant in the Gastroenterology Department, said the procedure was conducted on the patient after explaining the risk factor and benefit to the parents.

Dr. Singh described plasma exchange as a rare procedure.

After four cycles of the procedure supported by medical management, the patient became conscious, and her liver was functioning much better.

She was subsequently discharged from the hospital in a stable condition. She was able to consume normal food, Dr. Panda said.

Mohammed Nasim, the father of the patient, said that though he had taken his ailing daughter to several hospitals, she was not provided with the required treatment. Her problem was properly diagnosed and treated at SUMUM, leading to her recovery, he said, adds UNI.

Powered by WPeMatico

Early pregnancy HbA1c test allows effective screening for high risk mothers: Study

A new study found that early pregnancy HbA1c to be an effective screening test for high risk mothers and allows early intervention and reduce the need for oral glucose tolerance test (OGTT). The findings were published in the recent issue of The Lancet Diabetes & Endocrinology journal.

The STRiDE (Screening for Gestational Diabetes in Low- and Middle-Income Countries) study was conducted across seven centers in South India and seven centers in Western Kenya. Pregnant women aged 18 to 50 years and less than 16 weeks of gestation (less than 20 weeks in Kenya) were included after confirming their pregnancies by dating ultrasound. The study evaluated the effectiveness of early pregnancy HbA1c levels, both venous and capillary point-of-care, either alone or as part of a composite risk score including age, BMI and family history of diabetes to predict gestational diabetes at 24-28 weeks of gestation.

The STRiDE study from February 15, 2016 to December 13, 2019 enrolled a total of 3,070 participants in India and 4,104 in Kenya. Also, 4,320 participants from the PRiDE cohort in the UK were included for comparison. As diagnosed by OGTT at 24-28 weeks, the prevalence of gestational diabetes was found to be 19.2% in India, 3.0% in Kenya and 14.5% in the UK.

Early pregnancy HbA1c levels showed a significant independent association with the incidence of gestational diabetes at 24-28 weeks. The adjusted risk ratios were 1.60 in India, 3.49 in Kenya, and 4.72 in the UK.

Composite risk score models combined HbA1c with age, BMI and family history of diabetes and proved to be effective in predicting gestational diabetes. This innovative screening strategy used a population-specific two-threshold model to rule in or rule out gestational diabetes based on early pregnancy composite risk scores. This has the potential to reduce the need for OGTTs by 50-64%.

In the HbA1c-alone model, the thresholds for ruling in and ruling out gestational diabetes were determined as 5.4% and 4.9% in India, 6.0% and 5.2% in Kenya and 5.6% and 5.2% in the UK. Overall, the findings suggest that early pregnancy HbA1c is found to be an effective screening test for gestational diabetes by allowing women at highest risk to receive early intervention and significantly reducing the need for OGTTs.

Source:

Saravanan, P., Deepa, M., Ahmed, Z., Ram, U., Surapaneni, T., Kallur, S. D., Desari, P., Suresh, S., Anjana, R. M., Hannah, W., Shivashri, C., Hemavathy, S., Sukumar, N., Kosgei, W. K., Christoffersen-Deb, A., Kibet, V., Hector, J. N., Anusu, G., Stallard, N., … Mohan, V. (2024). Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts. In The Lancet Diabetes & Endocrinology. Elsevier BV. https://doi.org/10.1016/s2213-8587(24)00151-7

Powered by WPeMatico

ChatGPT AI-Empowered Echo Reports Simplify Findings and Save Time for Patients: Study

USA: New data suggests that using artificial intelligence (AI) to generate patient-friendly echocardiogram reports could save time and reduce confusion about findings before patients consult their clinicians. The findings were published online in JACC: Cardiovascular Imaging. 

Since the implementation of the 21st Century Cures Act in the United States in 2021, patients have had the right to access their medical test results immediately, often before their physicians have had a chance to review them.
Lior Jankelson, NYU Grossman School of Medicine, New York, NY, and colleagues examined whether ChatGPT, a generative AI that has shown effectiveness in generating echocardiogram reports, can help clinicians efficiently explain echocardiogram reports to patients.
For this purpose, the researchers utilized a HIPAA-compliant ChatGPT (OpenAI) model to review and rewrite reports for 100 transthoracic echocardiograms from their institution. The median patient age was 66, with 23% presenting LV systolic dysfunction.
The AI-generated summaries were typically shorter than the full echocardiogram reports, with a median length of 1,216 characters compared to 2,150 characters. Five cardiologists assessed the rewrites, finding that 29% could be accepted without edits, 44% were acceptable with some revisions, 13% were neutral, and 14% were deemed unacceptable. Regarding accuracy, 84% of the rewrites were classified as “all true,” while 16% were considered “mostly correct.”
Of the 16 AI-generated rewrites with inaccuracies, eight were deemed “potentially dangerous,” four required correction but were not considered dangerous, and four had errors that were unlikely to need correction.
Regarding the relevance of the rewrites, cardiologists found that 76% included “all of the important information,” 15% included “most,” 7% had “about half,” and 2% contained “less than half.” None of the rewrites with missing information were rated as “potentially dangerous.” Nine required corrections but posed no danger, one had an “indeterminate need for correction,” six were unlikely to need correction, and 12 were deemed “insignificant.”
In terms of representing quantitative information, cardiologists strongly agreed with 54% of the rewrites, agreed with 36%, were neutral about 2%, and disagreed with 1%.
Twelve nonclinical reviewers assessed the rewrites for understandability. Compared to the original reports, 70% found the AI rewrites “much more” understandable, 27% “a little more,” and 3% “equally” understandable. While 15% and 35% felt the rewrites would “strongly” and “slightly” reduce their worry, respectively, half were neutral or felt more anxious about the patient-oriented reports. However, 85% of nonclinical reviewers preferred having the AI-generated rewrites alongside the original reports. Inter-rater reliability was low among echocardiographers and only fair among nonclinical reviewers.
“Low inter-rater reliability of the study highlights that physicians vary significantly in their ECG report styles. This variation underscores the potential benefit of developing AI systems that could integrate individual practice patterns and preferences into the generated reports,” the researchers concluded.
Reference:
Martin JA, Saric M, Vainrib AF, et al. Evaluating patient-oriented echocardiogram reports augmented by artificial intelligence. JACC Imaging. 2024;Epub ahead of print.

Powered by WPeMatico

increasing evidence that sugar substitute erythritol raises cardiovascular risk, reports Cleveland Clinic study

New Cleveland Clinic research shows that consuming foods with erythritol, a popular artificial sweetener, increases risk of cardiovascular events such as heart attack and stroke. The findings, from a new intervention study in healthy volunteers, show erythritol made platelets (a type of blood cell) more active, which can raise the risk of blood clots. Sugar (glucose) did not have this effect.

Published in Arteriosclerosis, Thrombosis and Vascular Biology, the research adds to increasing evidence that erythritol may not be as safe as currently classified by food regulatory agencies and should be reevaluated as an ingredient. The study was conducted by a team of Cleveland Clinic researchers as part of a series of investigations on the physiological effects of common sugar substitutes.

“Many professional societies and clinicians routinely recommend that people at high cardiovascular risk – those with obesity, diabetes or metabolic syndrome – consume foods that contain sugar substitutes rather than sugar,” said senior and corresponding author Stanley Hazen, M.D., Ph.D., chair of Cardiovascular and Metabolic Sciences in Cleveland Clinic’s Lerner Research Institute and co-section head of Preventive Cardiology. “These findings underscore the importance of further long-term clinical studies to assess the cardiovascular safety of erythritol and other sugar substitutes.”

Erythritol and other artificial sweeteners are common replacements for table sugar in low-calorie, low-carbohydrate and “keto” products. Erythritol is about 70% as sweet as sugar and is produced through fermenting corn. After ingestion, erythritol is poorly metabolized by the body. Instead, it goes into the bloodstream and leaves the body mainly through urine. The human body creates low amounts of erythritol naturally, so any additional consumption can accumulate.

Erythritol is classified by the U.S. Food and Drug Administration and the European Food Safety Authority as a GRAS (“generally recognized as safe”) ingredient, allowing its use without restriction in food products. This is primarily because it is a sugar alcohol found naturally in fruits and vegetables and a byproduct of glucose metabolism in human tissue, although in small quantities.

However, recent studies by Dr. Hazen’s group, have found evidence that erythritol in typically consumed amounts may increase cardiovascular risk.

The current research builds on the team’s previous study, published last year in Nature Medicine, which revealed that cardiac patients with high erythritol levels were twice as likely to experience a major cardiac event in the following three years compared to those with low levels. The study also discovered that adding erythritol to patients’ blood or platelets increased clot formation. These findings were confirmed by pre-clinical studies.

The new human intervention study was designed to more directly observe the effects on platelets following erythritol ingestion at a dose typically contained in a “sugarless” soda or muffin. In 20 healthy volunteers, researchers found that the average erythritol level after eating increased over 1,000 times in the group that consumed erythritol compared to their initial levels. Results also revealed participants showed a significant increase in blood clot formation after consuming erythritol, but no change was observed after consuming glucose.

“This research raises some concerns that a standard serving of an erythritol-sweetened food or beverage may acutely stimulate a direct clot-forming effect,” said study co-author W. H. Wilson Tang, M.D., research director for Heart Failure and Cardiac Transplantation Medicine at Cleveland Clinic. “Erythritol and other sugar alcohols that are commonly used as sugar substitutes should be evaluated for potential long-term health effects especially when such effects are not seen with glucose itself.”

He adds that the results of this study are especially notable because they come on the heels of another recent study by this research group showing that xylitol, another common artificial sweetener, produced similar increases in plasma levels and affected platelet aggregation in healthy volunteers the same way. Like erythritol, studies with xylitol also included large-scale observation studies demonstrating that high xylitol levels are associated with increased risk of heart attack, stroke or death over the following three years.

The authors note that further clinical studies assessing the long-term cardiovascular safety of erythritol are warranted.

“I feel that choosing sugar-sweetened treats occasionally and in small amounts would be preferable to consuming drinks and foods sweetened with these sugar alcohols, especially for people at elevated risk of thrombosis such as those with heart disease, diabetes or metabolic syndrome,” Dr. Hazen advises. “Cardiovascular disease builds over time, and heart disease is the leading cause of death globally. We need to make sure the foods we eat aren’t hidden contributors.”

The research is part of Dr. Hazen’s ongoing investigation into factors that contribute to residual cardiovascular risk. His team follows patients over time and finds chemical signatures in blood that can predict the future development of heart and metabolic disease. He has made pioneering discoveries in atherosclerosis and inflammatory disease research, including the seminal discovery linking gut microbial pathways to cardiovascular disease and metabolic diseases.

Dr. Hazen also directs Cleveland Clinic’s Center for Microbiome and Human Health and holds the Jan Bleeksma Chair in Vascular Cell Biology and Atherosclerosis.  

Reference:

Marco Witkowski, Jennifer Wilcox, Valesha Province, Zeneng Wang, Ina Nemet, W.H. Wilson Tang, Ingestion of the Non-Nutritive Sweetener Erythritol, but Not Glucose, Enhances Platelet Reactivity and Thrombosis Potential in Healthy Volunteers, Arteriosclerosis Thrombosis and Vascular Biology, https://doi.org/10.1161/ATVBAHA.124.321019.

Powered by WPeMatico

Regular BP monitoring during postpartum period prevents Delayed initiation of Antihypertensives and CV risk: JAMA

Denmark: A recent study has shed light on the patterns of antihypertensive medication use among women in the first two years following childbirth. The research, published in JAMA Network Open, suggests that routine, systematic postpartum blood pressure (BP) monitoring could help prevent delays in starting antihypertensive medications, ultimately enhancing cardiovascular disease (CVD) prevention among women.

This cohort study involving 784,782 women revealed that the use of antihypertensive medications postpartum was higher among those with severe hypertensive disorders of pregnancy (HDP), early diagnosis, and prior antenatal medication use.

“Within two years of delivery, up to 44.1% of women with HDPs and 1.8% of those with normotensive pregnancies began medication. Notably, 24.9% of women with HDPs and 76.7% of women with normotensive pregnancies initiated treatment more than three months postpartum,” the researchers reported.

Women who experience HDP are known to face a well-documented risk of developing chronic hypertension within a few years after delivery; however, the management of postpartum hypertension in these individuals remains inconsistent. Considering this, Frederikke Lihme, Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark, and colleagues aimed to evaluate the frequency of initiating antihypertensive medication within the first two years postpartum, considering both HDP status and prior use of antihypertensives during pregnancy.

This Danish register-based cohort study analyzed data from women who had at least one pregnancy lasting 20 or more gestational weeks and delivered between January 1, 1995, and December 31, 2018, focusing only on their first pregnancy within this period. Statistical analysis was performed from October 2022 to September 2023.

The study investigated hypertensive disorders of pregnancy as the exposure and assessed the cumulative incidences and hazard ratios of initiating antihypertensive medication within two years postpartum, across five postpartum time intervals, concerning HDP status and antenatal medication use.

The following were the key findings of the study:

  • The cohort included 784 782 women, of whom 4.7% had an HDP (HDP: median age at delivery, 29.1 years; no HDP: median age at delivery, 29.0 years).
  • The 2-year cumulative incidence of initiating postpartum antihypertensive treatment ranged from 1.8% among women who had not had HDPs to 44.1% among women with severe preeclampsia who required antihypertensive medication during pregnancy.
  • Most women who required postpartum antihypertensive medication after an HDP initiated use within three months of delivery (severe preeclampsia, 86.6%; preeclampsia, 75.3%; and gestational hypertension, 75.1%).
  • 13.4% of women with severe preeclampsia, 24.7.% of women with preeclampsia, 24.9% of women with gestational hypertension, and 76.7% of those without an HDP first filled a prescription for antihypertensive medication more than three months after delivery.
  • Women with gestational hypertension had the highest rate of initiating medication after more than one year postpartum, with 11.6% starting treatment after this period.
  • Among women who filled a prescription in the first three months postpartum, up to 55.9% required further prescriptions more than three months postpartum, depending on HDP status and antenatal medication use.

Based on the findings, the researchers stress that heightened awareness among both affected women and healthcare professionals about the elevated risk of chronic hypertension following hypertensive disorders of pregnancy (HDP) is crucial.

“Timely detection and effective management of persistent postpartum hypertension are essential to mitigating the cardiovascular disease risks linked to HDPs. Future research should focus on identifying the most effective strategies for delivering this care,” the authors concluded.

Reference:

Lihme F, Basit S, Thilaganathan B, Boyd HA. Patterns of Antihypertensive Medication Use in the First 2 Years Post Partum. JAMA Netw Open. 2024;7(8):e2426394. doi:10.1001/jamanetworkopen.2024.26394

Powered by WPeMatico

Study evaluates Optimisation of Table Height for Supraglottic Airway Device Insertion

Supraglottic airway devices (SADs) are utilized for airway maintenance during anesthesia procedures. Recent study aimed to investigate the impact of operating table height on supraglottic airway device (SAD) insertion and task performance. The researchers conducted a randomized controlled trial with 90 patients to determine the appropriate table height during SAD insertion in terms of time taken for insertion, success rate, ease of insertion, and anesthesiologist comfort. The patients were divided into three groups, and the table height was adjusted so that the patient’s forehead was at the level of 5 cm above the xiphoid process in group I, at the level of the xiphoid process in group II, and at the level of 5 cm below the xiphoid process in group III of the anesthesiologist. The study measured SAD insertion time, first attempt success rate, ease of insertion, and anesthesiologist comfort during the procedure.

Results and Conclusion

The results revealed that the SAD insertion time was lower in group III than in groups I and II, and a significant difference was found between the groups. Additionally, the mean ease of insertion score, anesthesiologist comfort, and the first-attempt success rate of SAD insertion were higher in group III than in groups I and II, with statistically significant differences. The study concluded that the lower table height with the patient’s forehead at the level of 5 cm below the xiphoid process of the anesthesiologist is ergonomically more efficient during SAD insertion and also more comfortable for the anesthesiologist. The study highlighted the importance of proper positioning of the patient’s head and the level of the patient in relation to the anesthesiologist, as improper positioning can lead to physical problems such as cervical disc pain, mental workload, and poor task performance.

The study utilized a randomized controlled trial design and was conducted from August 2021 to January 2022. The trial involved ASA physical status I and II patients, aged between 18 and 60 years, with mallampati of grade I and II. The primary outcome of the study was the SAD insertion time, which was significantly lower in group III than in groups I and II. The secondary outcomes, including the first-attempt success rate, ease of insertion, and anesthesiologist comfort, were also higher in group III than in group I and group II, with statistically significant differences among the groups. The study also mentioned the importance of appropriate operating table height in relation to the anesthesiologist during SAD insertion and the potential impact on the comfort and efficiency of the procedure.

Key Points

– A randomized controlled trial was conducted to investigate the impact of operating table height on supraglottic airway device (SAD) insertion and task performance in 90 patients.

– The patients were divided into three groups, where the table height was adjusted to position the patient’s forehead at different levels in relation to the anesthesiologist’s xiphoid process. – The study measured SAD insertion time, first attempt success rate, ease of insertion, and anesthesiologist comfort during the procedure.

– Results showed that the SAD insertion time was lower, ease of insertion score was higher, anesthesiologist comfort was improved, and the first-attempt success rate of SAD insertion was higher when the table height positioned the patient’s forehead at the level of 5 cm below the xiphoid process of the anesthesiologist.

– The study concluded that lower table height with the patient’s forehead at the level of 5 cm below the xiphoid process of the anesthesiologist is ergonomically more efficient during SAD insertion and also more comfortable for the anesthesiologist.

– The study utilized a randomized controlled trial design and highlighted the importance of proper positioning of the patient’s head and level of the patient in relation to the anesthesiologist during SAD insertion, as improper positioning can lead to physical problems and poor task performance.

Reference –

Kumari P, Kumar A, Sinha C, Kumar A. Effect of table height on supraglottic airway insertion (I‑gel): A randomized control trial. J Anaesthesiol Clin Pharmacol.2024

Powered by WPeMatico

Crinecerfont outperforms placebo in lowering increased androstenedione levels in young Congenital adrenal hyperplasia patients: NEJM

United States:
A recent study published in The New England Journal of Medicine concluded
that crinecerfont performed a placebo in reducing increasing androstenedione
levels in Congenital adrenal hyperplasia pediatric participants.
Crinecerfont was also associated with decrease in glucocorticoid dose from
supraphysiologic to physiologic levels.

Congenital Adrenal
Hyperplasia is a genetic condition that affects the adrenal gland located at
the top of each kidney. It is a group of rare inherited autosomal recessive
disorders characterized by the deficiency of one of the enzymes that are needed
to make specific hormones. The formation
of too little cortisol, too little aldosterone and too many androgens are the
symptoms of CAH. It occurs due to 21-hydroxylase deficiency and requires
treatment with glucocorticoids, usually at supraphysiologic doses, to address
cortisol insufficiency and reduce excess adrenal androgens. Considering this Kyriakie Sarafoglou, M.D
from the University of Minnesota Medical School and College of Pharmacy,
Minneapolis (K.S.) et.al, conducted a study to evaluate the effect of
crinecerfont in Pediatric patients with Congenital Adrenal Hyperplasia.

In order to do this, the
study team carried out an international, randomized experiment in which
pediatric CAH patients were randomly allocated to receive a placebo for 28
weeks at a ratio of 2:1. They maintained a stable glucocorticoid dose for 4
weeks, then they adjust the dose for the target of 8.0 to 10.0 mg per square
meter of body- surface area per day.

A total of 103
participants were randomly assigned to the study. They move the baseline
aldosterone level’s primary efficacy end point to week 4. The percentage change
in glucocorticoid dosage from baseline to week 28 with androstenedione control
maintained was the secondary endpoint.

The study revealed that:

  • At 28 weeks, 100 (97%) of the 69
    participants who were assigned to crinecerfont and 34 who received a placebo
    were still in the trial.
  • The
    mean androstenedione level was 431 ng per deciliter (15.0 nmol/liter) and the
    mean glucocorticoid dose was 16.4 mg per square meter per day at baseline.
  • By week four, androstenedione levels in the
    crinecerfont group were significantly lower (−197 ng per deciliter) while they
    were higher (71 ng per deciliter) in the placebo group.
  • Before the morning glucocorticoid dose, the
    observed mean androstenedione value was 208 ng per deciliter (7.3 nmol/liter)
    in the crinecerfont group and 545 ng per deciliter (19.0 nmol/liter) in the
    placebo group.
  • By week 28, the mean glucocorticoid dosage had
    increased by 5.6% with placebo but had dropped by 18.0% with crinecerfont
    (while maintaining androstenedione control).
  • The most frequent side effects were vomiting,
    pyrexia, and headaches.

“Crinecerfont was more
effective than a placebo in children with CAH at lowering elevated levels of
androstenedione. It was also linked to a reduction in glucocorticoid dosage
from supraphysiologic to physiologic levels while maintaining androstenedione
management”, the researchers concluded.

Reference

Sarafoglou, K., Kim, M.
S., Lodish, M., Felner, E. I., Martinerie, L., Nokoff, N. J., Clemente, M.,
& the CAHtalyst Pediatric Trial Investigators. (2024). Phase 3 trial of
crinecerfont in pediatric congenital adrenal hyperplasia. New England
Journal of Medicine, 391
(6), 493-503. https://doi.org/10.1056/NEJMoa2404655

Powered by WPeMatico